Research programme: small molecule drug discovery program - Critical Outcome Technologies/Delmar Chemicals Inc.
Latest Information Update: 16 Jul 2016
At a glance
- Originator Critical Outcome Technologies; Delmar Chemicals
- Developer Critical Outcome Technologies
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Canada
- 12 Sep 2012 Early research in Undefined indications in Canada (unspecified route)